{"id":63210,"date":"2026-04-15T20:48:55","date_gmt":"2026-04-15T12:48:55","guid":{"rendered":"https:\/\/flcube.com\/?p=63210"},"modified":"2026-04-15T20:48:56","modified_gmt":"2026-04-15T12:48:56","slug":"johnson-johnson-reports-strong-q1-2026-sales-growth-despite-net-earnings-decline-raises-full-year-guidance","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63210","title":{"rendered":"Johnson &amp; Johnson Reports Strong Q1 2026 Sales Growth Despite Net Earnings Decline; Raises Full-Year Guidance"},"content":{"rendered":"\n<p><strong>Johnson &amp; Johnson<\/strong> (J&amp;J, <a href=\"https:\/\/www.google.com\/finance\/quote\/JNJ:NYSE\">NYSE: JNJ<\/a>) reported <strong>first-quarter 2026 results<\/strong> on April 14, 2026, showcasing robust <strong>sales growth of 9.9% year-over-year (YOY)<\/strong> to <strong>USD 24.1 billion<\/strong>, while <strong>net earnings declined 52.4% YOY<\/strong> to <strong>USD 5.2 billion<\/strong>. The company has <strong>increased its full-year 2026 guidance<\/strong>, now expecting <strong>reported sales of USD 100.8 billion<\/strong> (7.0% growth at the midpoint).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-performance-summary\">Financial Performance Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Q1 2026<\/th><th>YOY Change<\/th><\/tr><\/thead><tbody><tr><td><strong>Reported Sales<\/strong><\/td><td>USD 24.1 billion<\/td><td>+9.9%<\/td><\/tr><tr><td><strong>Net Earnings<\/strong><\/td><td>USD 5.2 billion<\/td><td>-52.4%<\/td><\/tr><tr><td><strong>Full-Year 2026 Guidance<\/strong><\/td><td>USD 100.8 billion<\/td><td>+7.0% (midpoint)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-business-segment-performance\">Business Segment Performance<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-innovative-medicine\">Innovative Medicine<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Worldwide Operational Sales<\/strong>: USD 15.4 billion (+7.4% YOY)<\/li>\n\n\n\n<li><strong>Acquisition Impact<\/strong>: +1.8% growth primarily from <strong>CAPLYTA (Lumateperone)<\/strong><\/li>\n\n\n\n<li><strong>Key Growth Drivers<\/strong>:<\/li>\n\n\n\n<li><strong>Oncology<\/strong>: DARZALEX (Daratumumab), CARVYKTI (Ciltacabtagene Autoleucel), ERLEADA (Apalutamide), RYBREVANT (Amivantamab)\/LAZCLUZE (Lazertinib)<\/li>\n\n\n\n<li><strong>Immunology<\/strong>: TREMFYA (Guselkumab)<\/li>\n\n\n\n<li><strong>Neuroscience<\/strong>: SPRAVATO (Esketamine)<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-medtech\">MedTech<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Worldwide Operational Sales<\/strong>: USD 8.6 billion (+4.6% YOY)<\/li>\n\n\n\n<li><strong>Key Growth Drivers<\/strong>:<\/li>\n\n\n\n<li><strong>Cardiovascular<\/strong>: Electrophysiology products, Abiomed, Shockwave<\/li>\n\n\n\n<li><strong>Orthopaedics<\/strong>: Trauma products<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regional-performance\">Regional Performance<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Region<\/th><th>Q1 2026 Sales<\/th><th>YOY Growth<\/th><\/tr><\/thead><tbody><tr><td><strong>United States<\/strong><\/td><td>USD 13.3 billion<\/td><td>+8.3%<\/td><\/tr><tr><td><strong>International<\/strong><\/td><td>USD 10.7 billion<\/td><td>+3.9%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-analysis\">Strategic Analysis<\/h2>\n\n\n\n<p>The significant <strong>decline in net earnings<\/strong> despite strong sales growth likely reflects one-time charges, increased R&amp;D investments, or restructuring costs\u2014common in pharmaceutical companies undergoing portfolio optimization. However, J&amp;J&#8217;s decision to <strong>raise full-year guidance<\/strong> demonstrates confidence in underlying business momentum and operational execution.<\/p>\n\n\n\n<p><strong>Innovative Medicine<\/strong> continues to be the primary growth engine, with oncology assets showing particularly strong performance. The success of <strong>CARVYKTI<\/strong>, J&amp;J&#8217;s BCMA-targeted CAR-T therapy developed with Legend Biotech, highlights the company&#8217;s strategic positioning in next-generation cancer immunotherapies.<\/p>\n\n\n\n<p><strong>MedTech<\/strong> segment shows steady recovery and growth, with cardiovascular innovations from recent acquisitions (Abiomed, Shockwave) contributing meaningfully to performance. This validates J&amp;J&#8217;s acquisition strategy in high-growth medical technology subsectors.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-implications\">Market Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Investor Confidence<\/strong>: Raised guidance suggests management&#8217;s confidence in sustainable growth trajectory<\/li>\n\n\n\n<li><strong>Portfolio Strength<\/strong>: Diversified growth across therapeutic areas reduces dependency on single products<\/li>\n\n\n\n<li><strong>Geographic Balance<\/strong>: Strong performance in both U.S. and international markets provides revenue stability<\/li>\n\n\n\n<li><strong>Innovation Pipeline<\/strong>: Continued investment in high-value therapeutic areas supports long-term growth<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-forward-outlook\">Forward Outlook<\/h2>\n\n\n\n<p>J&amp;J&#8217;s raised guidance positions the company for another year of above-market growth in the healthcare sector. The balanced performance across Innovative Medicine and MedTech segments, combined with geographic diversification, provides resilience against market volatility.<\/p>\n\n\n\n<p>The company&#8217;s focus on high-value innovative therapies in oncology, immunology, and neuroscience\u2014coupled with strategic MedTech acquisitions\u2014creates multiple avenues for sustained growth through 2026 and beyond.<\/p>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding financial performance, guidance, and business outlook. Actual results may differ due to risks including regulatory changes, competitive pressures, clinical trial outcomes, and global economic conditions affecting healthcare markets.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1Q26-Earnings-Press-Release-Final-Draft-04-13-26_10AM-with-attachments.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 1Q26-Earnings-Press-Release-Final-Draft-04-13-26_10AM-with-attachments.\"><\/object><a id=\"wp-block-file--media-0809f201-0d52-4ba9-a9ec-ad721e7f6890\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1Q26-Earnings-Press-Release-Final-Draft-04-13-26_10AM-with-attachments.pdf\">1Q26-Earnings-Press-Release-Final-Draft-04-13-26_10AM-with-attachments<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1Q26-Earnings-Press-Release-Final-Draft-04-13-26_10AM-with-attachments.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-0809f201-0d52-4ba9-a9ec-ad721e7f6890\">Download<\/a><\/div>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/JNJ-Earnings-Presentation-Q1-2026-Final.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of JNJ-Earnings-Presentation-Q1-2026-Final.\"><\/object><a id=\"wp-block-file--media-4d4fa1e1-d4db-455b-92dd-155e4ee06ee7\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/JNJ-Earnings-Presentation-Q1-2026-Final.pdf\">JNJ-Earnings-Presentation-Q1-2026-Final<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/JNJ-Earnings-Presentation-Q1-2026-Final.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-4d4fa1e1-d4db-455b-92dd-155e4ee06ee7\">Download<\/a><\/div>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1Q26-Other-Financial-Disclosures.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 1Q26-Other-Financial-Disclosures.\"><\/object><a id=\"wp-block-file--media-f90039a9-a30b-48f7-88a7-f83778f46d0c\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1Q26-Other-Financial-Disclosures.pdf\">1Q26-Other-Financial-Disclosures<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1Q26-Other-Financial-Disclosures.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-f90039a9-a30b-48f7-88a7-f83778f46d0c\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Johnson &amp; Johnson (J&amp;J, NYSE: JNJ) reported first-quarter 2026 results on April 14, 2026, showcasing&#8230;<\/p>\n","protected":false},"author":1,"featured_media":63216,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[27,150,149,858],"class_list":["post-63210","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-finanical-reports","tag-jj","tag-johnson-johnson","tag-nyse-jnj"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Johnson &amp; Johnson Reports Strong Q1 2026 Sales Growth Despite Net Earnings Decline; Raises Full-Year Guidance - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Johnson &amp; Johnson (J&amp;J, NYSE: JNJ) reported first-quarter 2026 results on April 14, 2026, showcasing robust sales growth of 9.9% year-over-year (YOY) to USD 24.1 billion, while net earnings declined 52.4% YOY to USD 5.2 billion. The company has increased its full-year 2026 guidance, now expecting reported sales of USD 100.8 billion (7.0% growth at the midpoint).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63210\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Johnson &amp; Johnson Reports Strong Q1 2026 Sales Growth Despite Net Earnings Decline; Raises Full-Year Guidance\" \/>\n<meta property=\"og:description\" content=\"Johnson &amp; Johnson (J&amp;J, NYSE: JNJ) reported first-quarter 2026 results on April 14, 2026, showcasing robust sales growth of 9.9% year-over-year (YOY) to USD 24.1 billion, while net earnings declined 52.4% YOY to USD 5.2 billion. The company has increased its full-year 2026 guidance, now expecting reported sales of USD 100.8 billion (7.0% growth at the midpoint).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63210\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-15T12:48:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-15T12:48:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1501-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63210#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63210\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Johnson &amp; Johnson Reports Strong Q1 2026 Sales Growth Despite Net Earnings Decline; Raises Full-Year Guidance\",\"datePublished\":\"2026-04-15T12:48:55+00:00\",\"dateModified\":\"2026-04-15T12:48:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63210\"},\"wordCount\":449,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63210#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1501-1.webp\",\"keywords\":[\"Finanical Reports\",\"J&amp;J\",\"Johnson &amp; Johnson\",\"NYSE: JNJ\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63210#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63210\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63210\",\"name\":\"Johnson &amp; Johnson Reports Strong Q1 2026 Sales Growth Despite Net Earnings Decline; Raises Full-Year Guidance - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63210#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63210#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1501-1.webp\",\"datePublished\":\"2026-04-15T12:48:55+00:00\",\"dateModified\":\"2026-04-15T12:48:56+00:00\",\"description\":\"Johnson & Johnson (J&J, NYSE: JNJ) reported first-quarter 2026 results on April 14, 2026, showcasing robust sales growth of 9.9% year-over-year (YOY) to USD 24.1 billion, while net earnings declined 52.4% YOY to USD 5.2 billion. The company has increased its full-year 2026 guidance, now expecting reported sales of USD 100.8 billion (7.0% growth at the midpoint).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63210#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63210\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63210#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1501-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1501-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Johnson & Johnson Reports Strong Q1 2026 Sales Growth Despite Net Earnings Decline; Raises Full-Year Guidance\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63210#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Johnson &amp; Johnson Reports Strong Q1 2026 Sales Growth Despite Net Earnings Decline; Raises Full-Year Guidance\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Johnson &amp; Johnson Reports Strong Q1 2026 Sales Growth Despite Net Earnings Decline; Raises Full-Year Guidance - Insight, China&#039;s Pharmaceutical Industry","description":"Johnson & Johnson (J&J, NYSE: JNJ) reported first-quarter 2026 results on April 14, 2026, showcasing robust sales growth of 9.9% year-over-year (YOY) to USD 24.1 billion, while net earnings declined 52.4% YOY to USD 5.2 billion. The company has increased its full-year 2026 guidance, now expecting reported sales of USD 100.8 billion (7.0% growth at the midpoint).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63210","og_locale":"en_US","og_type":"article","og_title":"Johnson &amp; Johnson Reports Strong Q1 2026 Sales Growth Despite Net Earnings Decline; Raises Full-Year Guidance","og_description":"Johnson & Johnson (J&J, NYSE: JNJ) reported first-quarter 2026 results on April 14, 2026, showcasing robust sales growth of 9.9% year-over-year (YOY) to USD 24.1 billion, while net earnings declined 52.4% YOY to USD 5.2 billion. The company has increased its full-year 2026 guidance, now expecting reported sales of USD 100.8 billion (7.0% growth at the midpoint).","og_url":"https:\/\/flcube.com\/?p=63210","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-15T12:48:55+00:00","article_modified_time":"2026-04-15T12:48:56+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1501-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63210#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63210"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Johnson &amp; Johnson Reports Strong Q1 2026 Sales Growth Despite Net Earnings Decline; Raises Full-Year Guidance","datePublished":"2026-04-15T12:48:55+00:00","dateModified":"2026-04-15T12:48:56+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63210"},"wordCount":449,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=63210#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1501-1.webp","keywords":["Finanical Reports","J&amp;J","Johnson &amp; Johnson","NYSE: JNJ"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63210#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63210","url":"https:\/\/flcube.com\/?p=63210","name":"Johnson &amp; Johnson Reports Strong Q1 2026 Sales Growth Despite Net Earnings Decline; Raises Full-Year Guidance - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=63210#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=63210#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1501-1.webp","datePublished":"2026-04-15T12:48:55+00:00","dateModified":"2026-04-15T12:48:56+00:00","description":"Johnson & Johnson (J&J, NYSE: JNJ) reported first-quarter 2026 results on April 14, 2026, showcasing robust sales growth of 9.9% year-over-year (YOY) to USD 24.1 billion, while net earnings declined 52.4% YOY to USD 5.2 billion. The company has increased its full-year 2026 guidance, now expecting reported sales of USD 100.8 billion (7.0% growth at the midpoint).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63210#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63210"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=63210#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1501-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1501-1.webp","width":1080,"height":608,"caption":"Johnson & Johnson Reports Strong Q1 2026 Sales Growth Despite Net Earnings Decline; Raises Full-Year Guidance"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63210#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Johnson &amp; Johnson Reports Strong Q1 2026 Sales Growth Despite Net Earnings Decline; Raises Full-Year Guidance"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1501-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63210","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63210"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63210\/revisions"}],"predecessor-version":[{"id":63217,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63210\/revisions\/63217"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/63216"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63210"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63210"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63210"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}